Galapagos Trio of Posters: Disposition, Comparative Metabolism and Excretion of 14C-Ziritaxestat

Poster Authors:

Ray Cooke¹, Kathryn Webbley¹, Dylan Williams¹, Jess Richardson¹, Hayley Bradshaw¹, Claire Henson¹, Caroline Sabadie², Eric Helmer³

1 Pharmaron UK Ltd, Rushden, UK;

² Galapagos SASU, Romainville, France

³ Galapagos Biotech Limited, Cambridge, UK

As part of Pharmaron’s end-to-end services, we’ve recently completed an ADME integrated program for Ziritaxestat, an autotaxin inhibitor designed for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis. This work was performed on behalf of Galapagos NV. Here we showcase a series of posters, presented at ISSX 2021, describing the 14C ADME studies performed during the development of the molecule.  Our integrated support included the radiosynthesis of both non-GMP and clinical GMP batches, a comprehensive rat ADME package, and an evaluation of the metabolism of Ziritaxestat in accordance with the FDA “MIST” guidance.